Table 1.
Baseline demographic and clinical characteristics (N = 592)
| Characteristics | |
|---|---|
| Mean age, y (SD) | 57.0 (15.0) |
| Male, N (%) | 342 (57.8) |
| Mean body mass index, kg/m2 (SD) | 28.2 (5.3) |
| Previous DVT contralateral, N (%) | 70 (10.1) |
| Provoked thrombosis, N (%) | 182 (30.7) |
| DVT location, N (%) | |
| Popliteal vein | 309 (52.2) |
| Femoral vein | 163 (27.5) |
| Common femoral vein | 119 (20.1) |
| Left leg | 312 (52.7) |
| Right leg | 275 (46.5) |
| Bilateral | 5 (0.8) |
| DVT treatment (%) | |
| Vitamin K antagonist* | 477 (80.6) |
| Nonvitamin K anticoagulants† | 18 (3.0) |
| Investigational anticoagulants‡ | 61 (11.1) |
| Low molecular weight heparin | 26 (4.4) |
| Duration anticoagulant therapy (days) | 258 (178) |
| Average time from diagnosis to second ultrasound, months (SD) | 5.3 (1.9) |
| Compression therapy in the acute phase of DVT (%) | |
| No initial compression | 72 (12.2) |
| Initial compression therapy | 520 (87.8) |
| Multilayer compression bandaging | 369 (62.3) |
| Compression hosiery | 151 (25.5) |
*
All patients with vitamin K antagonist had initially 5 to 10 days of low molecular weight heparin.
†
The only direct oral anticoagulants used during the study was rivaroxaban.
‡
Some patients participated in studies comparing investigational anticoagulants (warfarin vs edoxaban), low molecular weight heparin in patients with malignancy.